Supplements don't need FDA approval. The Health Secretary says peptides shouldn't either.

He is right about supplements. He is wrong about peptides. Dietary supplements do reach the market without FDA approval — that is how the law has worked since 1994, and it is a real, deliberate exemption. Injectable peptides are not in that category, and the gap between the two is the whole story. FDA's own scientists disagreed with the Secretary in writing. An advisory committee then split the difference. Nothing has changed in law yet, and no injectable peptide is regulated as a supplement today.

Here is what was actually said, by whom, and what still has to happen.

What the Secretary has said

Kennedy has made the comparison directly. Speaking to a member of Congress in April 2026, he argued that FDA does not require safety studies for drugs that aren't mass marketed with specific claims and indications — the framework that governs supplements under the 1994 Dietary Supplement Health and Education Act.

He has been personal about it. On Joe Rogan's podcast in late February 2026 he described himself as a fan of peptides and said he had used them, adding that he hoped they would end up somewhere people could get them from ethical suppliers.

His broader position is about who decides. On a longevity podcast in 2025, discussing stem cells, chelation, vitamins and peptides, he argued FDA should do the science and report it but "don't tell physicians what they can and cannot prescribe."

That argument has a real basis. Restriction has not stopped peptide use — it moved it to unregulated overseas vendors selling material with no enforceable identity, potency or sterility standard. Prohibition arguments of this shape are not fringe, and anyone who has watched the gray market grow understands the point.

Where FDA's scientists landed

Somewhere else. Ahead of the July meeting, FDA scientists concluded there was insufficient evidence to recommend the peptides under review, noting that some have not been studied in humans at all. The agency posted those concerns publicly before the panel convened.

The committee met July 23–24, 2026 and considered seven peptides for the 503A bulk drug substances list. A divided panel voted to recommend broader access despite those researchers' calls for caution. Six of seven were recommended — BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. One, Emideltide (DSIP), was not.

We publish that last fact because nobody else will. A committee that considered seven and declined one was not rubber-stamping. It also means the six that cleared did so on their own merits, which is a stronger position than a clean sweep would have been.

Who is pushing for this, and what they sell

This part is usually left out, and it shouldn't be.

Among the loudest advocates is Gary Brecka, a self-described longevity expert and prominent Make America Healthy Again figure. He sells peptide injectables, patches and nasal sprays through his website at roughly $350 to $600 each, and Kennedy has appeared on his podcast to promise an end to FDA's posture on peptides. Wire coverage of the July meeting named him alongside Joe Rogan as a leading proponent.

Two details in that reporting matter more than the politics.

Some of what is sold isn't among the peptides that were reviewed. Brecka's catalogue includes ipamorelin and CJC-1295. Neither was one of the seven substances the advisory committee considered in July, and both remain in FDA's restrictive category. CJC-1295's clinical development was halted in 2006 after a participant death and never restarted.

The vials are labelled research use only. That labelling is how these products are sold lawfully — it is an assertion that the contents are not intended for human use. CNN reported that lawyers in the field describe it as an attempt to work around FDA regulation, and quoted a peptide forum coaching members to say they are "researching" rather than taking.

We say this plainly because it defines the choice a patient is actually making. A vial labelled research use only carries no enforceable identity, potency, sterility or endotoxin standard. Nobody is required to guarantee what is in it, and if something goes wrong there is no party who has represented otherwise.

Why "like supplements" isn't a legal description

Three differences matter, and none of them are about whether peptides work.

A dietary ingredient and an injectable drug are different categories. DSHEA covers substances taken by mouth as food components. An injected peptide is a drug by route and intent, whatever it is made of. Supplement manufacturers have separately been pressing FDA to widen what counts as a dietary ingredient, which would open the door to marketing peptides that way. That is an active request, not current law.

503A listing is not approval, and it is not a supplement pathway either. Inclusion on the 503A bulk drug substances list would make a substance eligible for a licensed pharmacy to compound pursuant to a prescription. It is not a finding that the drug is safe or effective for anything, and these substances do not become approved drugs through this route.

A recommendation is not a rule. The meeting itself was announced in a Federal Register notice published April 16, 2026, which also opened public docket FDA-2025-N-6895 for written comment. FDA is now reviewing those comments and would have to act through notice-and-comment rulemaking before anything is added to the list. The agency usually follows its advisory committees and is not required to. As of today, nothing has changed in law.

One more distinction worth stating, because it is the most commonly misreported fact in this story: twelve peptides were removed from FDA's restrictive Category 2 in April 2026. That removal happened because the underlying nominations were withdrawn. It lifted a do-not-compound posture; it did not authorise compounding, and it did not move anything into Category 1.

The part that actually affects a patient

Strip out the politics and one question survives: what is in the vial?

A mislabeled supplement is wasted money. A mislabeled, under-potent or non-sterile injectable, or one carrying bacterial endotoxin, is a different problem, and no regulatory category changes that. The needle does not care which list the molecule is on.

That is where the comparison breaks down at the bedside rather than in the statute. Whatever happens with rulemaking, an injected compound needs identity confirmation, potency verification, sterility testing and endotoxin testing — and a certificate of analysis showing purity by HPLC does not establish the last three.

This is our position and it does not move with the policy. We prescribe what a licensed compounding pharmacy can lawfully fill. For everything else we tell patients exactly where the process stands and notify them when it changes. We do not sell research compounds to patients, and we do not send them elsewhere to buy them.

What to watch

• Whether FDA opens rulemaking on the six recommended substances, and on what timeline
• Whether the dietary-ingredient definition is widened — a separate and larger change than the 503A question
• What happens to DSIP, the one that was declined

We track all of it on our 503A status page and update this page whenever the docket moves.

Written by Frank Muscarello, founder of Elevate Chicago. Frank is not a clinician; this page is regulatory reporting, not medical advice. Sources verified August 27, 2026. Independent clinical review pending.